Treatment of liver-limited metastatic colorectal cancer.
Although liver metastases from colorectal cancer previously conferred a very dismal prognosis, advances in systemic therapy combined with surgical techniques now gives these patients a reasonable chance for cure. Traditional cytoxic chemotherapy combined with biologic agents result in impressive response rates, allowing a portion of patients who were considered unresectable to undergo hepatectomy with curative intent. This review discusses the role of systemic therapy in patients with liver-limited metastatic disease for patients with resectable, potentially resectable and unresectable disease.
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA. hubbard.joleen@mayo.edu
Joleen M
JM
Hubbard
Steven R
SR
Alberts
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001685:Biological Factors / Q000627:therapeutic use*; D016461:Chemoembolization, Therapeutic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000187:drug effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery
D000970:Antineoplastic Agents; D001685:Biological Factors